Form 4: LifeStance Health CTO Granted Over 178,000 Restricted Stock Units

LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich was granted 178,571 restricted stock units, aligning his interests with shareholder value.

Summary

• Vukasin Paunovich, Chief Technology Officer of LifeStance Health Group, Inc. (LFST), acquired 178,571 shares of common stock.
• The acquisition was in the form of Restricted Stock Units (RSUs), where each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The transaction occurred on June 11, 2025, with a reported price of $0 per unit, indicating a grant rather than a purchase.
• Following this transaction, Mr. Paunovich beneficially owns 178,571 shares.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the RSU grant aligns the CTO's interests with shareholder value, which is generally viewed favorably. It's a routine compensation event, not indicative of major news, hence not highly positive.

Positives

• The grant of Restricted Stock Units (RSUs) to the Chief Technology Officer aligns management's long-term interests with those of shareholders.
• RSUs are a common form of equity compensation, incentivizing key executives to contribute to the company's growth and performance.

Negatives

• The future vesting of these RSUs could lead to a slight dilution of existing shareholder equity, although this is a standard aspect of equity compensation plans.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This insider transaction by a key technology executive at LifeStance Health Group, a provider of mental healthcare services, reflects ongoing efforts within the healthcare sector to align executive compensation with long-term company performance. Equity grants are a common practice across industries, including healthcare, to retain talent and incentivize growth in a competitive market.

Comparison to Industry Standards

• The grant of 178,571 Restricted Stock Units to a Chief Technology Officer is a standard practice for executive compensation in publicly traded companies, particularly in the healthcare and technology sectors.
• While specific comparable companies or projects are not detailed in this filing, similar RSU grants are routinely observed at companies like Teladoc Health (TDOC) or Amwell (AMWL) for their senior executives, reflecting a common approach to incentivize long-term value creation and retain key talent in the digital health space.
• The $0 acquisition price is typical for RSU grants as they represent a contingent right to receive shares upon vesting, rather than a direct purchase.

Stakeholder Impact

• Shareholders: Potential for slight future dilution upon vesting of RSUs, but also improved alignment of executive incentives with long-term shareholder value.
• Employees: May signal stability and commitment from senior leadership.

Next Steps

• The Restricted Stock Units will typically vest over a specified period, at which point they will convert into shares of LifeStance Health Group, Inc. common stock.

Key Dates

Keywords

LifeStance Health Group, LFST, Vukasin Paunovich, Chief Technology Officer, CTO, Restricted Stock Units, RSU, Insider Transaction, SEC Form 4, Equity Compensation, Healthcare Services, Mental Health